Skip to content
Search our Site
Search our site
Search our site
My PD Journey
About the EPDA
Political affairs and policy
Medical and pharmaceutical
Political and policy
World PD Day News
Resources and publications
Acorda presents data on inhaled levodopa therapy CVT-301 at International Congress of Parkinson's Disease and Movement Disorders
Acorda Therapeutics, Inc. today presented data from a Phase 2b clinical trial of CVT-301, an inhaled levodopa (L-dopa) under development for the episodic treatment of OFF episodes associated with Parkinson's disease (PD).
16 June 2015
Acadia Pharmaceuticals presents integrated data from phase III program with Nuplazid™ (pimavanserin) for Parkinson's psychosis
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the presentation of integrated efficacy and tolerability data from its Phase III program with NUPLAZID™ (pimavanserin) at the 19th International Congress of Parkinson's Disease and Movement Disorders held in San Diego.
16 June 2015
Gene therapy prevents Parkinson's disease in animal model, says Pitt study
Gene therapy to reduce production of a brain protein successfully prevented development of Parkinson's disease in an animal study, according to researchers at the University of Pittsburgh School of Medicine.
15 June 2015
NTCELL clinical study in Parkinson's meets endpoints
Living Cell Technologies Limited (LCT) today announced results from a Phase I/IIa clinical study of NTCELL, an experimental regenerative cell therapy being studied as a disease-modifying agent in Parkinson's disease.
14 June 2015
FDA approves brain implant to help reduce Parkinson's disease and essential tremor symptoms
The U.S. Food and Drug Administration today approved the Brio Neurostimulation System, an implantable deep brain stimulation device to help reduce the symptoms of Parkinson's disease and essential tremor, a movement disorder that is one of the most common causes of tremors.
12 June 2015
NeuroDerm announces start of a pharmacokinetic, head-to-head comparison study of ND0612H and Duodopa
NeuroDerm, Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that it has started a pharmacokinetic (PK) clinical study to determine the dosing of the company's lead product candidate, ND0612H, a subcutaneously administered liquid formulation of levodopa (LD) and carbidopa (CD), for the treatment of advanced Parkinson's Disease.
11 June 2015
There's finally something awesome to do with Google Glass
Google Glass was a failure. At least, according to most people. But not for one specific group: people with Parkinson's. They've been experimenting with new software for Glass and say that it improves the quality of their lives.
10 June 2015
Melior Discovery receives patent approval from U.S. Patent and Trademark Office for new Parkinson's disease drug candidate
Melior Discovery, Inc. announced today that the United States Patent and Trademark Office (USTPO) has awarded a patent to the company for its Parkinson's disease candidate, MLR-1019. The patent covers the use of this therapeutic for treating dyskinesia associated with L-DOPA therapy in Parkinson's disease.
10 June 2015
Amarantus opens clinical trial site & patient enrolment for eltoprazine phase 2b study in Parkinsons levodopa-induced dyskinesia
Amarantus BioScience Holdings, Inc., a biotechnology company announced that the first clinical trial site is now open for enrolment for the Phase 2b study of its lead product candidate eltoprazine for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).
05 June 2015
Global Kinetics raises $14.8m to take its Parkinson's tech to the US
Australian health technology company Global Kinetics Corporation (GKC) has raised $14.8 million to expand its Parkinson's disease treatment technology to the United States.
02 June 2015
Subscribe to this page >
Back to Top
Add page to PDF basket
Copyright © 2015 EPDA. All Rights Reserved.
Privacy and cookies